ITX-5061: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 56843466 |
| CHEMBL ID | 3402567 |
| MeSH ID | M0587840 |
| Synonym |
|---|
| itx-5061 |
| 1252679-52-9 |
| unii-j4ra8k2q2a |
| 1-naphthaleneacetamide, n-(5-(1,1-dimethylethyl)-2-methoxy-3- ((methylsulfonyl)amino)phenyl)-4-(2-(4-morpholinyl)ethoxy)-alpha-oxo-, hydrochloride (1:1) |
| j4ra8k2q2a , |
| itx 5061 |
| 1-naphthaleneacetamide, n-(5-(1,1-dimethylethyl)-2-methoxy-3-((methylsulfonyl)amino)phenyl)-4-(2-(4-morpholinyl)ethoxy)-.alpha.-oxo-, hydrochloride (1:1) |
| kc706 |
| kc-706 |
| CHEMBL3402567 |
| HY-19900 |
| CS-0016951 |
| itx5061 |
| n-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide;hydrochloride |
| itx-5061 hydrochloride ; itx 5061 hcl ; itx506 hcl pound>>itx5061 hydrochloride pound>>itx 5061 hydrochloride |
| itx-5061 hcl |
| BCP30784 |
| Q27281205 |
| EX-A4531 |
| MS-30777 |
| AKOS040741891 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Six subjects had grade ≥ 3 adverse events (one in placebo); none were treatment related." | ( Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. Amorosa, V; Bhattacharya, D; Coughlin, K; Glesby, MJ; Johnson, VA; Kang, M; Matining, R; Morse, GD; Sulkowski, MS; Wong-Staal, F; Wyles, D, 2014) | 0.4 |
| "Oral ITX5061 150 mg/day for up to 28 days was safe and well tolerated." | ( Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. Amorosa, V; Bhattacharya, D; Coughlin, K; Glesby, MJ; Johnson, VA; Kang, M; Matining, R; Morse, GD; Sulkowski, MS; Wong-Staal, F; Wyles, D, 2014) | 0.4 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " SPRY2-deficient CRPC is dependent on cholesterol bioavailability and SRB1-mediated tumoral cholesterol uptake for androgen biosynthesis." | ( Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. Ahmad, I; Blomme, A; Edwards, J; Fleming, J; Hamdy, FC; Harle, V; Hedley, A; Leung, HY; Loveridge, C; Mackay, G; Mui, E; Patel, R; Repiscak, P; Salji, M; Sansom, OJ; Teo, K; van den Broek, N, 2018) | 0.48 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Scavenger receptor class B member 1 | Mus musculus (house mouse) | IC50 (µMol) | 0.7700 | 0.0550 | 0.4617 | 0.7700 | AID1195631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1195631 | Inhibition of mouse SR-B1 overexpressed in CHO cells assessed as inhibition of [3H]cholesteryl ester uptake into cells after 2 to 3 hrs by liquid scintillation counting | 2015 | Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10 | Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (33.33%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (55.56%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||